What’s the current market cap for Pfizer stock?

Pfizer (PFE) has a market cap of $146bn as of June 09, 2026.

What is the P/E ratio for Pfizer stock?

The price to earnings (P/E) ratio for Pfizer (PFE) stock is 19.52 as of June 09, 2026.

Does Pfizer stock pay dividends?

Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of June 09, 2026, the dividend rate is $1.72 and the yield is 6.71%. Pfizer has a payout ratio of 130.54% on a trailing twelve-month basis.

When is the next Pfizer dividend payment date?

The next Pfizer (PFE) dividend payment is scheduled for June 12, 2026.

What is the beta indicator for Pfizer?

Pfizer (PFE) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Pfizer stock | $PFE Share Price

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Ticker

$PFE

Sector

Health

Primary listing

NYSE

Employees

75,000

Headquarters

New York, United States

Website

www.pfizer.com

Pfizer Metrics

BasicAdvanced

$146bn

19.52

$1.31

0.31

$1.72

6.71%

What the Analysts think about Pfizer

Analyst ratings (Buy, Hold, Sell) for Pfizer stock.

Bulls say / Bears say

Pfizer expects to regain stronger growth after 2028, driven by obesity drugs under development, an extended patent for its cardiovascular drug Vyndamax, and a favorable European court ruling on its COVID-19 vaccine.

In the first quarter of 2026, Pfizer surpassed Wall Street targets for both revenue and profit, benefitting from strong demand for its blood thinner Eliquis and recent acquisitions such as Padcev and Nurtec ODT.

The company is moving forward with a next-generation pneumococcal vaccine covering 35 bacterial strains, with clinical trials starting in 2026, underscoring its strong research and development pipeline.

On December 16, 2025, Pfizer forecasted its 2026 adjusted profit at $2.80–$3.00 per share, falling short of analysts’ average estimate of $3.05, due to expected lower sales of its COVID-19 vaccine and treatment products.

Pfizer’s 2026 revenue outlook includes about a $1.5 billion drop in COVID-19 product sales and a further $1.5 billion negative impact as key drug patents expire, limiting top-line growth for the year.

The drug price reductions promised to the U.S. government under a Trump-era pricing agreement are set to squeeze Pfizer’s prescription drug margins in 2026, putting more pressure on profitability.

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.

Pfizer Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Pfizer Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Pfizer News

AllArticlesVideos

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Forbes·6 hours ago

U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Business Wire·1 day ago

US FDA approves Pfizer's bleeding disorder drug for children

Reuters·1 day ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.